Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Barnett, A H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barnett, A H
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 50:397-407 (1994)
© 1994 The British Council

research-article

Diabetes and hypertension

A H Barnett

University of Birmingham, Birmingham Heartlands Hospital Birmingham, UK

Abstract

Hypertension is about twice as common in diabetics as in non-diabetics. The increased prevalence may relate to insulin resistance and its sequelae. Hypertension is a major risk factor for both large and small vessel disease, contributing to accelerated atherogenesis and progression of diabetic nephropathy and retinopathy. Treating raised blood pressure in diabetics is beneficial in the context of large vessel disease and in slowing progression of overt nephropathy. There is controversy as to whether antihypertensives, and particularly ACE inhibitor drugs, will prevent progression from incipient to overt nephropathy. All the major classes of antihypertensives can be used in diabetics, but the thiazide diuretics and p-blockers have metabolic side-effects which make them less appropriate as first line agents. The calcium antagonists and ACE inhibitors have better metabolic profiles and the latter reduce insulin resistance. ACE inhibitors may also have a renal protective effect in incipient nephropathy although the studies have been fairly short-term and with small patient numbers. Although ACE inhibitors and calcium antagonists are suitable as first line antihypertensives in diabetics, evidence is still lacking that these drugs reduce morbidity and mortality over and above that seen with other antihypertensives.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
N. Alfaidy, S. Gupta, C. DeMarco, I. Caniggia, and J. R. G. Challis
Oxygen Regulation of Placental 11{beta}-Hydroxysteroid Dehydrogenase 2: Physiological and Pathological Implications
J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4797 - 4805.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
T. Rosenthal, Y. Erlich, E. Rosenmann, and A. Cohen
Effects of Enalapril, Losartan, and Verapamil on Blood Pressure and Glucose Metabolism in the Cohen-Rosenthal Diabetic Hypertensive Rat
Hypertension, June 1, 1997; 29(6): 1260 - 1264.
[Abstract] [Full Text]

Home page
 The Diabetes EducatorHome page
J. Hinson, K. Riordan, D. Hemphill, C. Randolph, and V. Fonseca
Hypertension Education: An Important and Neglected Part of the Diabetes Education Curriculum?
The Diabetes Educator, January 1, 1997; 23(2): 166 - 170.
[PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.